Last 12 months
Inside the activity.
1 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2019 Filed Nov 6, 2019 01:56 UTC |
White Marvin LDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 189,894 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001019056-19-000620 · white.xml · derivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,894 Underlying: Common Stock · 189,894 shares Expires 2029-10-31 F1 · derivative.exercise_date: The options vest on November 1, 2020, the one-year anniversary of the grant date. Read SEC document |
| November 01, 2019 Filed Nov 6, 2019 01:55 UTC |
Mitchell ShawnteSVP, GC and Corporate Affairs
|
GrantStock Option (right to buy) · Derivative | 120,968 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001019056-19-000618 · mitchell.xml · derivative · entry 1 Mitchell Shawnte · CIK 0001749432 · SVP, GC and Corporate Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,968 Underlying: Common Stock · 120,968 shares Expires 2029-10-31 F1 · derivative.exercise_date: The options vest on November 1, 2020, the one-year anniversary of the grant date. Read SEC document |
| November 01, 2019 Filed Nov 6, 2019 01:53 UTC |
Lamothe Jeffrey G.SVP, CFO and Treasurer
|
GrantStock Option (right to buy) · Derivative | 135,384 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001019056-19-000614 · lamothe.xml · derivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,384 Underlying: Common Stock · 135,384 shares Expires 2029-10-31 F1 · derivative.exercise_date: The options vest on November 1, 2020, the one-year anniversary of the grant date. Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 08:29 UTC |
Maddux Randy JoeSVP Operations, CMO
|
PurchaseCommon Stock | 25,000 | $0.76 | $19,000.00 |
DisclosureSEC source: 0001019056-19-000487 · maddux_4.xml · nonDerivative · entry 1 Maddux Randy Joe · CIK 0001683826 · SVP Operations, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 01:46 UTC |
El-Hibri FuadDirector
|
PurchaseCommon Stock | 100,000 | $0.76 | $75,520.00 |
DisclosureSEC source: 0001019056-19-000476 · elhibri.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,124,536 F1 · kind: The transaction reported on this Form 4 was made by the Reporting Person pursuant to a trading plan adopted on May 31, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported represents the weighted average price of shares purchased in multiple transactions at prices ranging from $0.4999 to $0.8000 per share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 22:49 UTC |
El-Hibri FuadDirector · 10% owner
|
PurchaseCommon Stock | 55,015 | $0.83 | $45,860.50 |
DisclosureSEC source: 0001593968-19-001685 · primary_01.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,024,536 F1 · price: The purchase price of $0.8336 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.81 to $0.85. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 23, 2019 Filed Jul 24, 2019 22:49 UTC |
El-Hibri FuadDirector · 10% owner
|
PurchaseCommon Stock | 10,000 | $0.90 | $8,996.00 |
DisclosureSEC source: 0001593968-19-001652 · primary_01.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 969,521 F1 · price: The purchase price of $0.8996 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.89 to $0.90. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 22, 2019 Filed Jul 23, 2019 20:19 UTC |
El-Hibri FuadDirector · 10% owner
|
PurchaseCommon Stock | 30,000 | $0.89 | $26,601.00 |
DisclosureSEC source: 0001593968-19-001649 · primary_01.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 959,521 F1 · price: The purchase price of $0.8867 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.88 to $0.90. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 19, 2019 Filed Jul 19, 2019 22:18 UTC |
El-Hibri FuadDirector · 10% owner
|
PurchaseCommon Stock | 26,460 | $0.90 | $23,739.91 |
DisclosureSEC source: 0001593968-19-001645 · primary_01.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 929,521 F1 · price: The purchase price of $0.8972 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.88 to $0.90. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 21:12 UTC |
El-Hibri FuadDirector · 10% owner
|
PurchaseCommon Stock | 14,404 | $0.87 | $12,596.30 |
DisclosureSEC source: 0001593968-19-001642 · primary_01.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 903,061 F1 · price: The purchase price of $0.8745 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.86 to $0.89. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 17, 2019 Filed Jul 18, 2019 20:50 UTC |
El-Hibri FuadDirector · 10% owner
|
PurchaseCommon Stock | 19,136 | $0.87 | $16,703.81 |
DisclosureSEC source: 0001593968-19-001640 · primary_01.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 888,657 F1 · price: The purchase price of $0.8729 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.86 to $0.88. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 16, 2019 Filed Jul 16, 2019 21:54 UTC |
El-Hibri FuadDirector · 10% owner
|
PurchaseCommon Stock | 11,375 | $0.85 | $9,661.93 |
DisclosureSEC source: 0001593968-19-001632 · primary_01.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 869,521 F1 · price: The purchase price of $0.8494 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.84 to $0.85. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 11, 2019 Filed Jul 12, 2019 16:41 UTC |
El-Hibri FuadDirector · 10% owner
|
PurchaseCommon Stock | 14,691 | $0.85 | $12,453.56 |
DisclosureSEC source: 0001593968-19-001618 · primary_01.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 858,146 F1 · price: The purchase price of $0.8477 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.84 to $0.85. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 10, 2019 Filed Jul 11, 2019 20:10 UTC |
El-Hibri FuadDirector
|
PurchaseCommon Stock | 18,919 | $0.85 | $16,058.45 |
DisclosureSEC source: 0001019056-19-000402 · elhibri.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 843,455 F1 · price: The price reported represents the weighted average price of shares purchased in multiple transactions at prices ranging from $0.845 to $0.85 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| June 25, 2019 Filed Jun 25, 2019 23:11 UTC |
Abdun-Nabi DanielDirector
|
PurchaseCommon Stock | 16,667 | $0.90 | $15,000.30 |
DisclosureSEC source: 0001593968-19-001480 · primary_01.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,351 Read SEC document |
| June 14, 2019 Filed Jun 14, 2019 17:58 UTC |
White Marvin LDirector · President and CEO
|
PurchaseCommon Stock | 50,000 | $0.88 | $44,000.00 |
DisclosureSEC source: 0001593968-19-001428 · primary_01.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,603 F1 · price: The purchase price of $0.88 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.85 to $0.88. Mr. White undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 14, 2019 Filed Jun 3, 2022 19:06 UTC |
Niederhuber JohnDirector
|
PurchaseCommon Stock | 714 | $0.91 | $649.74 |
DisclosureSEC source: 0001209191-22-033928 · doc4.xml · nonDerivative · entry 2 Niederhuber John · CIK 0001501240 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,516 F2 · shares: Reflects a 1-for-14 reverse stock split of the Issuer's common stock effective as of March 26, 2020. F2 · price: Reflects a 1-for-14 reverse stock split of the Issuer's common stock effective as of March 26, 2020. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 18:57 UTC |
Kunz Barbara LopezDirector
|
PurchaseCommon Stock | 10,000 | $0.85 | $8,481.00 |
DisclosureSEC source: 0001593968-19-001379 · primary_01.xml · nonDerivative · entry 1 Kunz Barbara Lopez · CIK 0001679970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| June 07, 2019 Filed Jun 7, 2019 19:19 UTC |
Harsanyi ZsoltDirector
|
PurchaseCommon Stock | 50,000 | $0.78 | $39,000.00 |
DisclosureSEC source: 0001593968-19-001344 · primary_01.xml · nonDerivative · entry 1 Harsanyi Zsolt · CIK 0001380184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 17:00 UTC |
Kunz Barbara LopezDirector
|
GrantOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001593968-19-001276 · primary_01.xml · derivative · entry 1 Kunz Barbara Lopez · CIK 0001679970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Aptevo Therapeutics Inc. common stock · 25,000 shares Expires 2029-06-01 F1 · derivative.exercise_date: The stock option was granted on June 1, 2019 and becomes exercisable in three equal annual installments beginning on June 1, 2020. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 17:02 UTC |
El-Hibri FuadDirector · 10% owner
|
GrantOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001593968-19-001278 · primary_01.xml · derivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Aptevo Therapeutics Inc. common stock · 25,000 shares Expires 2029-06-01 F1 · derivative.exercise_date: The stock option was granted on June 1, 2019 and becomes exercisable in three equal annual installments beginning on June 1, 2020. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 17:01 UTC |
Harsanyi ZsoltDirector
|
GrantOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001593968-19-001277 · primary_01.xml · derivative · entry 1 Harsanyi Zsolt · CIK 0001380184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Aptevo Therapeutics Inc. common stock · 25,000 shares Expires 2029-06-01 F1 · derivative.exercise_date: The stock option was granted on June 1, 2019 and becomes exercisable in three equal annual installments beginning on June 1, 2020. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 16:59 UTC |
Grant Grady IIIDirector
|
GrantOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001593968-19-001275 · primary_01.xml · derivative · entry 1 Grant Grady III · CIK 0001679966 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Aptevo Therapeutics Inc. common stock · 25,000 shares Expires 2029-06-01 F1 · derivative.exercise_date: The stock option was granted on June 1, 2019 and becomes exercisable in three equal annual installments beginning on June 1, 2020. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 16:58 UTC |
Niederhuber JohnDirector
|
GrantOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001593968-19-001274 · primary_01.xml · derivative · entry 1 Niederhuber John · CIK 0001501240 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Aptevo Therapeutics Inc. common stock · 25,000 shares Expires 2029-06-01 F1 · derivative.exercise_date: The stock option was granted on June 1, 2019 and becomes exercisable in three equal annual installments beginning on June 1, 2020. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 16:54 UTC |
Abdun-Nabi DanielDirector
|
GrantOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001593968-19-001273 · primary_01.xml · derivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Aptevo Therapeutics Inc. common stock · 25,000 shares Expires 2029-06-01 F1 · derivative.exercise_date: The stock option was granted on June 1, 2019 and becomes exercisable in three equal annual installments beginning on June 1, 2020. Read SEC document |
| May 31, 2019 Filed Jun 7, 2019 15:18 UTC |
Maddux Randy JoeSenior VP, Operations
|
PurchaseCommon Stock | 20,000 | $0.73 | $14,600.00 |
DisclosureSEC source: 0001593968-19-001343 · primary_01.xml · nonDerivative · entry 1 Maddux Randy Joe · CIK 0001683826 · Senior VP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| May 21, 2019 Filed May 21, 2019 22:12 UTC |
Grant Grady IIIDirector
|
PurchaseCommon Stock | 10,000 | $0.80 | $7,970.00 |
DisclosureSEC source: 0001593968-19-001154 · primary_01.xml · nonDerivative · entry 1 Grant Grady III · CIK 0001679966 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| May 20, 2019 Filed May 20, 2019 23:22 UTC |
White Marvin LDirector · President and CEO
|
PurchaseCommon Stock | 30,000 | $0.81 | $24,300.00 |
DisclosureSEC source: 0001593968-19-001149 · primary_01.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,603 Read SEC document |
| May 14, 2019 Filed May 15, 2019 01:27 UTC |
White Marvin LDirector · President and CEO
|
PurchaseCommon Stock | 10,000 | $0.78 | $7,800.00 |
DisclosureSEC source: 0001019056-19-000291 · white.xml · nonDerivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,603 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:04 UTC |
Gross Jane ASee Remarks
|
Exercise / conversionRestricted Stock Unit · Derivative | 9,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-19-000176 · gross.xml · derivative · entry 4 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,138 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. 9,140 shares of common stock underlying the RSUs vested on each of March 1, 2017 and March 1, 2018, and the remaining 9,138 shares vested on March 1, 2019. F3 · derivative.expiration_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. 9,140 shares of common stock underlying the RSUs vested on each of March 1, 2017 and March 1, 2018, and the remaining 9,138 shares vested on March 1, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:04 UTC |
Gross Jane ASee Remarks
|
Tax withholdingCommon Stock | 2,710 | $1.57 | $4,254.70 |
DisclosureSEC source: 0001019056-19-000176 · gross.xml · nonDerivative · entry 2 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,583 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:04 UTC |
Gross Jane ASee Remarks
|
Exercise / conversionCommon Stock | 9,138 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-19-000176 · gross.xml · nonDerivative · entry 1 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:09 UTC |
Stromatt Scott CChief Medical Officer and SVP
|
Exercise / conversionRestricted Stock Unit · Derivative | 16,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-19-000184 · stromatt.xml · derivative · entry 4 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,269 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vested in three equal annual installments beginning on the anniversary of the grant date. F3 · derivative.expiration_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vested in three equal annual installments beginning on the anniversary of the grant date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:09 UTC |
Stromatt Scott CChief Medical Officer and SVP
|
Tax withholdingCommon Stock | 4,823 | $1.57 | $7,572.11 |
DisclosureSEC source: 0001019056-19-000184 · stromatt.xml · nonDerivative · entry 2 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,183 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:09 UTC |
Stromatt Scott CChief Medical Officer and SVP
|
Exercise / conversionCommon Stock | 16,269 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-19-000184 · stromatt.xml · nonDerivative · entry 1 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:08 UTC |
Mitchell ShawnteSVP, GC and Corporate Affairs
|
Exercise / conversionRestricted Stock Unit · Derivative | 6,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-19-000182 · mitchell.xml · derivative · entry 4 Mitchell Shawnte · CIK 0001749432 · SVP, GC and Corporate Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,787 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into shares of the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 1, 2016 the reporting person was granted 20,365 restricted stock units. 6,789 shares of common stock underlying the restricted stock units vested on each of March 1, 2017 and March 1, 2018, and the remaining 6,787 shares vested on March 1, 2019. F3 · derivative.expiration_date: On March 1, 2016 the reporting person was granted 20,365 restricted stock units. 6,789 shares of common stock underlying the restricted stock units vested on each of March 1, 2017 and March 1, 2018, and the remaining 6,787 shares vested on March 1, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:08 UTC |
Mitchell ShawnteSVP, GC and Corporate Affairs
|
Tax withholdingCommon Stock | 2,012 | $1.57 | $3,158.84 |
DisclosureSEC source: 0001019056-19-000182 · mitchell.xml · nonDerivative · entry 2 Mitchell Shawnte · CIK 0001749432 · SVP, GC and Corporate Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,527 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:08 UTC |
Mitchell ShawnteSVP, GC and Corporate Affairs
|
Exercise / conversionCommon Stock | 6,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-19-000182 · mitchell.xml · nonDerivative · entry 1 Mitchell Shawnte · CIK 0001749432 · SVP, GC and Corporate Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into shares of the Issuer's common stock on a one-for-one basis. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:05 UTC |
Lamothe Jeffrey G.SVP and CFO
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-19-000178 · lamothe.xml · derivative · entry 4 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,318 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. 7,320 shares of common stock underlying the RSUs vested on each of March 1, 2017 and March 1, 2018, and the remaining 7,318 shares vested on March 1, 2019. F3 · derivative.expiration_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. 7,320 shares of common stock underlying the RSUs vested on each of March 1, 2017 and March 1, 2018, and the remaining 7,318 shares vested on March 1, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:05 UTC |
Lamothe Jeffrey G.SVP and CFO
|
Tax withholdingCommon Stock | 2,170 | $1.57 | $3,406.90 |
DisclosureSEC source: 0001019056-19-000178 · lamothe.xml · nonDerivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,024 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:05 UTC |
Lamothe Jeffrey G.SVP and CFO
|
Exercise / conversionCommon Stock | 7,318 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-19-000178 · lamothe.xml · nonDerivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:03 UTC |
Adelman MichaelSVP, Commercial Operations
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-19-000174 · adelman.xml · derivative · entry 4 Adelman Michael · CIK 0001749435 · SVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,318 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 1, 2016 the reporting person was granted 21,958 restricted stock units. 7,320 shares of common stock underlying the restricted stock units vested on each of March 1, 2017 and March 1, 2018, and the remaining 7,318 shares vested on March 1, 2019. F3 · derivative.expiration_date: On March 1, 2016 the reporting person was granted 21,958 restricted stock units. 7,320 shares of common stock underlying the restricted stock units vested on each of March 1, 2017 and March 1, 2018, and the remaining 7,318 shares vested on March 1, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:03 UTC |
Adelman MichaelSVP, Commercial Operations
|
Tax withholdingCommon Stock | 2,395 | $1.57 | $3,760.15 |
DisclosureSEC source: 0001019056-19-000174 · adelman.xml · nonDerivative · entry 2 Adelman Michael · CIK 0001749435 · SVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,426 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:03 UTC |
Adelman MichaelSVP, Commercial Operations
|
Exercise / conversionCommon Stock | 7,318 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-19-000174 · adelman.xml · nonDerivative · entry 1 Adelman Michael · CIK 0001749435 · SVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:06 UTC |
Maddux Randy JoeSVP Operations, CMO
|
GrantStock Option (right to buy) · Derivative | 67,400 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001019056-19-000180 · maddux_4.xml · derivative · entry 1 Maddux Randy Joe · CIK 0001683826 · SVP Operations, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,400 Underlying: Common Stock · 67,400 shares Expires 2029-02-28 F1 · derivative.exercise_date: The options vest in three approximately equal annual installments beginning on February 28, 2020. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 02:04 UTC |
Gross Jane ASee Remarks
|
GrantStock Option (right to buy) · Derivative | 67,400 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001019056-19-000176 · gross.xml · derivative · entry 3 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,400 Underlying: Common Stock · 67,400 shares Expires 2029-02-28 F2 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on February 28, 2020. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 02:10 UTC |
White Marvin LDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 151,600 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001019056-19-000186 · white.xml · derivative · entry 1 White Marvin L · CIK 0001493324 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,600 Underlying: Common Stock · 151,600 shares Expires 2029-02-28 F1 · derivative.exercise_date: The options vest in three approximately equal annual installments beginning on February 28, 2020. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 02:09 UTC |
Stromatt Scott CChief Medical Officer and SVP
|
GrantStock Option (right to buy) · Derivative | 67,400 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001019056-19-000184 · stromatt.xml · derivative · entry 3 Stromatt Scott C · CIK 0001679975 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,400 Underlying: Common Stock · 67,400 shares Expires 2029-02-28 F2 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on February 28, 2020. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 02:08 UTC |
Mitchell ShawnteSVP, GC and Corporate Affairs
|
GrantStock Option (right to buy) · Derivative | 67,400 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001019056-19-000182 · mitchell.xml · derivative · entry 3 Mitchell Shawnte · CIK 0001749432 · SVP, GC and Corporate Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,400 Underlying: Common Stock · 67,400 shares Expires 2029-02-28 F2 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on February 28, 2020. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 02:05 UTC |
Lamothe Jeffrey G.SVP and CFO
|
GrantStock Option (right to buy) · Derivative | 67,400 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001019056-19-000178 · lamothe.xml · derivative · entry 3 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,400 Underlying: Common Stock · 67,400 shares Expires 2029-02-28 F2 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on February 28, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.